image
Healthcare - Medical - Devices - NASDAQ - US
$ 2.3501
4.76 %
$ 13.8 M
Market Cap
-0.99
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VVOS stock under the worst case scenario is HIDDEN Compared to the current market price of 2.35 USD, Vivos Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VVOS stock under the base case scenario is HIDDEN Compared to the current market price of 2.35 USD, Vivos Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VVOS stock under the best case scenario is HIDDEN Compared to the current market price of 2.35 USD, Vivos Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VVOS

image
$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
15 M REVENUE
8.91%
-11.2 M OPERATING INCOME
35.41%
-11.1 M NET INCOME
18.02%
-12.7 M OPERATING CASH FLOW
-6.24%
-568 K INVESTING CASH FLOW
33.41%
17.9 M FINANCING CASH FLOW
63.65%
3.7 M REVENUE
-4.20%
-2.81 M OPERATING INCOME
-6.09%
-2.83 M NET INCOME
-8.02%
-2.94 M OPERATING CASH FLOW
29.78%
-165 K INVESTING CASH FLOW
14.06%
3.05 M FINANCING CASH FLOW
-19.36%
Balance Sheet Vivos Therapeutics, Inc.
image
Current Assets 7.47 M
Cash & Short-Term Investments 6.26 M
Receivables 430 K
Other Current Assets 783 K
Non-Current Assets 7.81 M
Long-Term Investments 0
PP&E 4.38 M
Other Non-Current Assets 3.43 M
40.96 %2.81 %5.12 %28.67 %22.44 %Total Assets$15.3m
Current Liabilities 4.98 M
Accounts Payable 1.1 M
Short-Term Debt 477 K
Other Current Liabilities 3.4 M
Non-Current Liabilities 2.35 M
Long-Term Debt 1.04 M
Other Non-Current Liabilities 1.32 M
14.98 %6.51 %46.43 %14.12 %17.97 %Total Liabilities$7.3m
EFFICIENCY
Earnings Waterfall Vivos Therapeutics, Inc.
image
Revenue 15 M
Cost Of Revenue 6.01 M
Gross Profit 9.02 M
Operating Expenses 20.2 M
Operating Income -11.2 M
Other Expenses -35 K
Net Income -11.1 M
20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)15m(6m)9m(20m)(11m)35k(11m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
60.00% GROSS MARGIN
60.00%
-74.32% OPERATING MARGIN
-74.32%
-74.09% NET MARGIN
-74.09%
-140.01% ROE
-140.01%
-72.86% ROA
-72.86%
-103.60% ROIC
-103.60%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vivos Therapeutics, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)20192019202020202021202120222022202320232024202420252025
Net Income -11.1 M
Depreciation & Amortization 581 K
Capital Expenditures 0
Stock-Based Compensation 762 K
Change in Working Capital -2.94 M
Others -1.62 M
Free Cash Flow -12.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Vivos Therapeutics, Inc.
image
VVOS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Vivos Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced a definitive agreement to acquire the operating assets of The Sleep Center of Nevada (“SCN”), the largest operator of medical sleep centers in Nevada. globenewswire.com - 2 weeks ago
Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company Participants Bradford Amman - CFO, Treasurer & Secretary Kirk Huntsman - Co-Founder, Chairman & CEO Conference Call Participants Guyn Kim - Water Tower Research Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vivos Therapeutics Full Year 2024 Earnings Conference Call. [Operator Instructions] This conference call is being recorded, and a replay of today's call will be available on the Investor Relations section of Vivos' website and will remain posted there for the next 30 days. seekingalpha.com - 1 month ago
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $3.05 per share a year ago. zacks.com - 1 month ago
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults) and moderate to severe OSA in children ages 6 - 17), today reported financial results and operating highlights for the full year ended December 31, 2024. globenewswire.com - 1 month ago
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced it plans to release its full year 2024 financial results after market close on Monday, March 31, 2025. globenewswire.com - 1 month ago
Vivos Therapeutics sees strong adoption of OSA treatment, expands strategic alliance Vivos Therapeutics (NASDAQ:VVOS) announced an expansion of its strategic marketing and distribution alliance with Rebis Health into two additional locations in Colorado. The company said initial data from the partnership showed that patients prefer Vivos CARE as a treatment for obstructive sleep apnea (OSA) nearly two to one over continuous positive airway pressure (CPAP) therapy, the current standard of care treatment. proactiveinvestors.com - 2 months ago
Best Momentum Stocks to Buy for January 8th VVOS, DXC and YELP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024. zacks.com - 3 months ago
New Strong Buy Stocks for January 8th SONY, VVOS, DXC, LIND and FNCO have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024. zacks.com - 3 months ago
Vivos Therapeutics announces funding boost Vivos Therapeutics (NASDAQ:VVOS) has announced definitive agreements for a registered direct offering and concurrent private placement expected to generate up to $6.9 million in gross proceeds The medical device company, which specializes in treatments for sleep-related breathing disorders, said the offering involves the sale of 709,220 shares at $4.935 per share, priced at-the-market under Nasdaq rules, generating gross proceeds of approximately $3.5 million before expenses. Additionally, the company will issue unregistered short-term warrants in a concurrent private placement. proactiveinvestors.com - 4 months ago
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 709,220 shares of its common stock at a purchase price of $4.935 per share in a registered direct offering priced at-the-market under Nasdaq rules. globenewswire.com - 4 months ago
All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 4 months ago
Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets. Operator Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 5 months ago
8. Profile Summary

Vivos Therapeutics, Inc. VVOS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 13.8 M
Dividend Yield 0.00%
Description Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Contact 9137 Ridgeline Boulevard, Highlands Ranch, CO, 80129 https://vivos.com
IPO Date Dec. 11, 2020
Employees 109
Officers Mr. John Ballard Senior Vice President of Technology Mr. Bradford K. Amman Chief Financial Officer, Treasurer & Secretary Ms. Susan McCullough Co-Founder & Executive Vice President of Operations Ms. Ruth Hembree Senior Vice President of Practice Services Mr. Nicholas M. DeGennaro Senior Vice President of Mergers and Acquisition Group Mr. R. Kirk Huntsman Co-Founder, Chairman of the Board & Chief Executive Officer Mr. Todd Huntsman Co-Founder & Senior Vice President of Product and Technology Ms. RaeAnn Byrnes Co-Founder and Senior Vice President of Events & Clinical Advisory Services